Each week, we take one short question from the world of pharmaceutical R&D and break it down with a quick, evidence-based multiple-choice challenge. Today’s Molecule Minute looks at a surprising bottleneck affecting small-molecule pipelines in 2024–2025.
Question
Several global analyses suggest that one particular development bottleneck is now responsible for the majority of delays in small-molecule programs moving from Phase II to Phase III. Which factor is most commonly cited?
A. Synthetic route complexity and evolving impurity profiles
B. Failure of preclinical toxicology models to predict human outcomes
C. Insufficient CMC readiness and lack of robust process validation
D. Sponsor hesitation due to commercial uncertainty
Answer: C. Insufficient CMC readiness and lack of robust process validation
Although scientific challenges persist, recent regulatory trend data show that insufficient Chemistry, Manufacturing, and Controls (CMC) maturity is now a leading cause of development delays. According to an FDA review of recent application deficiencies, incomplete stability programs, inadequate control strategies, and underdeveloped impurity methods frequently prevent sponsors from advancing to late-stage trials1. Independent analyses by the International Council for Harmonisation (ICH) have also emphasized the role of CMC gaps in prolonging development timelines, especially for complex small-molecule synthetic routes requiring advanced impurity characterization2.
Strengthening early-stage CMC planning—particularly analytical method robustness, validation strategies, and process-scale reproducibility—continues to be one of the most effective ways to accelerate small-molecule development across the global pipeline.
References
- U.S. Food and Drug Administration. Common Deficiencies and Best Practices for Premarket Applications. https://www.fda.gov ↩
- International Council for Harmonisation (ICH). Guideline Q11: Development and Manufacture of Drug Substances. https://www.ich.org ↩